ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
A bibliometric analysis of the current research status and hotspots regarding Aducanumab treatment for Alzheimer's disease.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prevalence of Alzheimer's disease is steadily increasing, and Aducanumab has garnered significant attention as a treatment since 2021. There is a growing body of research on Aducanumab and its relationship with Alzheimer's disease; however, there is currently a lack of bibliometric analysis regarding the use of Aducanumab in the treatment of Alzheimer's disease.
objectiveThis study employs bibliometric methods to analyze the current research landscape and hotspots surrounding Alzheimer's disease and Aducanumab, providing a reference for subsequent investigations in this field and the promotion of Aducanumab as a treatment for Alzheimer's disease.
methodsThis study retrieved articles related to Alzheimer's disease and Aducanumab from the WOS core database, covering the period from the establishment of the database until Dec 31, 2024. After a rigorous selection process, analyses were conducted using GraphPad Prism 10, VOSviewer, and CiteSpace to obtain insights into publication and citation metrics, collaboration networks among countries, institutions, and authors, as well as clustering analysis of reference papers and keywords.
resultsThe number of articles regarding Aducanumab treatment for Alzheimer's disease has been increasing annually, with a notable surge occurring after 2021. The three countries with the highest publication output are the United States, the United Kingdom, and China. The leading institutions in terms of publication volume are Biogen, Harvard Medical School, and the University of California, San Francisco. The top three authors contributing to this body of work are Poul F. Høilund-Carlsen, Abass Alavi, and Mona-Elisabeth Revheim. The journals with the highest publication rates include Alzheimer's & Dementia, the International Journal of Molecular Sciences, and the Journal of Alzheimer's Disease. The most cited article is "Lecanemab in Early Alzheimer's Disease," authored by van Dyck CH et al., published in 2023 in the New England Journal of Medicine. The ten most frequently occurring keywords are Alzheimer's disease, Aducanumab, dementia, amyloid-beta, immunotherapy, tau, a-beta, mouse model, amyloid, and mild cognitive impairment. The keyword and cluster "pharmacokinetics" currently represent a research hotspot in this field.
conclusionThis study employs bibliometric methods to reveal the publication trends related to Aducanumab in the context of Alzheimer's disease, examining collaborations among countries, regions, and authors, as well as recent research hotspots. It provides objective data that serves as a reference for scientific research and clinical practice concerning Aducanumab treatment for Alzheimer's disease.
Indexed as
Identifiers
40637746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.